Fluvoxamine Maleate

马来酸氟伏沙明

Report date: 2026/04/22 20:01:10
NME

Base Information

Drug NameFluvoxamine Maleate
Drug Alias Name氟伏沙明Fluvoxaminum马来酸氟伐沙明马来酸氟戊肟胺Depromel +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin reuptake inhibitors
TargetsSerotonin transporter
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromePhobia, Social +[12] 
Global Approved IndicationsObsessive-Compulsive DisorderDepression
Approved Indications in ChinaObsessive-Compulsive DisorderDepression
Original Approved Country/TerritorySwitzerland
Original Approved Date1983/01/01
Country/TerritoryCanadaUnited StatesHungary +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSolvay Sa
China Registration ClassN/A

Develop Information

Active CompaniesAbbott Healthcare Products BvWashington University School Of MedicineSolvay Sa +[5] 
Inactive CompaniesAbbvie IncJazz Pharmaceuticals PlcNational Institute Of Mental Health (Nimh)
Active IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromeObsessive-Compulsive Disorder +[7] 
Inactive IndicationsPhobia, SocialAnxiety DisordersAnxiety +[5] 

Other Information

ATC CodeN06AB08
Related LinksWikipediaDrugBankKEGG